Fact Source: Financial Supervisory Service DART / 2025-11-04
Disclosure Type: Supply Contract / Single Sales Contract (Amendment)
💡 3-Second Summary
Samsung Biologics has revised its existing contract manufacturing organization (CMO) agreement, increasing the total contract value from KRW 241.9B to KRW 517.8B (an increase of KRW 275.8B) and extending the contract duration and non-disclosure period by three years to December 31, 2033.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Contract Name: Contract Manufacturing Agreement
- Contract Amount Alteration: Before: KRW 241,973,146,733 → After: KRW 517,856,145,079 (Increased by USD 200,147,271 from the previous USD 175,546,392 to a final confirmed USD 375,693,663, calculated at the initial exchange rate of KRW 1,378.40/USD on May 23, 2025)
- Net Increase in Contract Value: KRW 275,882,998,346 (In KRW equivalent)
- Ratio to Recent Sales: Before: 5.32% → After: 11.39% (Compared to the 2024 consolidated financial statement revenue of KRW 4,547,322,176,421)
- Counterparty: A pharmaceutical company located in Europe (Kept confidential due to business secrets)
- Contract Period: May 23, 2025 ~ December 31, 2033 (The expiration date has been extended by three years from December 31, 2030)
- Reason for Amendment: Change in contract amount and extension of contract period at the client’s request
- Amendment Item (Disclosure Postponement Period): Before: 2030-12-31 → After: 2033-12-31
- Other Terms: No down payment or advance payment is included. The final contract end date and total amount may be altered upon mutual agreement.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This filing serves as a material amendment to the existing manufacturing contract, updating key operational terms rather than simply adjusting administrative timelines. Unlike pure non-disclosure extensions, this corporate action significantly lifts the overall confirmed contract value, signaling an expansion in the company’s order backlog and mid-to-long-term revenue fundamental layout.
The most critical metrics for market participants to register is the expansion of the contract size, which grew by over USD 200.14M (approximately KRW 275.8B) to reach a total of KRW 517.8B. This adjustment raises the contract’s weight relative to the 2024 consolidated revenue from 5.32% to 11.39%, creating a potential impact that strengthens long-term pipeline visibility. Along with the change in contract value, both the contract maturity date and the corresponding confidentiality period have been pushed out by three years to the end of 2033. This specific filing does not explain the concrete causes behind separate earnings performance fluctuations or the specific reasons for the contract changes.
In conclusion, this disclosure stands out as an amendment event where both the contract amount and duration have been modified simultaneously. While future adjustments remain possible based on subsequent mutual agreements, market participants should monitor this arrangement based on the expanded scale of the contract framework.
📝 Editor’s Comment (by K-STOCK Editor)
This latest amendment stands in contrast to previous routine confidentiality extensions filed by Samsung Biologics. It represents a genuine shift in order scale, with the contract value growing by approximately KRW 275.8B (USD 200.14M) due to the change in contract amount requested by the client. With the revenue-to-contract ratio now exceeding 11%, long-term revenue predictability has strengthened significantly. Along with the contract amount modification, the contract period and the non-disclosure deadline have been extended to the end of 2033. Although the true identity of this European pharmaceutical partner will remain sealed for an additional three years, the tangible upward revision in confirmed metrics is clearly verified by the disclosure facts. Investors should remain mindful of fluid contract terms down the road while focusing on the reinforced backlog scale.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
